

INVESTOR BRIEFING NOTICE

MELBOURNE, Australia, 22 March 2023: Dimerix Limited (ASX: DXB) a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, is pleased to advise that CEO & Managing Director, Dr Nina Webster, will be presenting at the Emergence23 Wholesale Investor conference in Sydney on 24 March 2023.

Key points that will be covered:

- Phase 3 global clinical trial in FSGS kidney disease patients status and update
- Advanced partnering negotiations with material offers received from multiple parties for various territories¹
- Commercial opportunity and addressable market value

The 8 minute presentation will be live and online, and investors can register ahead to attend the presentation here: https://www.emergence.wholesaleinvestor.com/attend-sydney

The presentation is attached to this announcement.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster Dimerix Limited Chief Executive Officer & Managing Director Tel: +61 1300 813 321 E: investor@dimerix.com Rudi Michelson Monsoon Communications Tel: +61 3 9620 3333 Mob: +61 (0)411 402 737 E: rudim@monsoon.com.au

Follow us on LinkedIn and Twitter

Authorised for lodgement by the Board of the Company

—END—

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. info@dimerix.com

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042.

In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a trial in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any trial, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease. DMX-200 is also under investigation as a potential treatment for acute respiratory distress syndrome (ARDS) in patients with COVID-19.

FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old.² For those who are fortunate enough to receive a kidney transplant, approximately 60% will get re-occurring FSGS in the transplanted kidney.³ At this time, there are no drugs specifically approved for FSGS anywhere in the world, so the treatment options and prognosis are poor.

FSGS is a billion-dollar plus market: the number of people with FSGS in the US alone is just over 80,000,² and worldwide about 220,000.⁴ The illness has a global compound annual growth rate of 8%, with over 5,400 new cases diagnosed in the US alone each year.⁵ Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX-200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.

References

- 1 Offers are non-binding and subject to due diligence, a definitive agreement and board approval
- 2 Guruswamy Sangameswaran KD, Baradhi KM. (2021) Focal Segmental Glomerulosclerosis), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/

5 Nephcure Kidney International (2020); Focal Segmental Glomerulosclerosis, online https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/

³ Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669

⁴ Delve Insight Market Research Report (2022): Focal segmental glomerulosclerosis (FSGS) – Market Insight, Epidemiology and market forecast – 2032; https://www.delveinsight.com/report-store/focal-segmentalglomerulosclerosis-fsgs-market

ACTION3 FSGS CLINICAL STUDY



Developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease

(ASX:DXB)

Wholesale Investor Presentation

March 2023

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

Late stage, phase 3 clinical development asset





Near term Phase 3 interim analysis, and potential accelerated approval pathway

Advanced partnering negotiations with offers received from multiple parties for various territories¹

Comprehensive development plan to ensure commercial ready

Orphan Drug status providing protection through data exclusivity²

Growing global market forecasted to exceed \$3b by 2032³



Strong progress to date in recruitment, managed by an experienced team and global CRO

Significantly de-risked, late-stage development program



Strong safety profile¹



Proven efficacy¹



Completed toxicology studies²








Clear development pathway to market⁴



Orphan Drug designations⁵



Targeting orphan disease

Orphan designation created incentives for companies to develop new drugs for rare diseases



Commercially attractive pricing structure

(~US\$120,000 potential cost per year based on rare kidney treatments¹, average US orphan drug price of \$84,000/year in 2018²)

Opportunity for accelerated approval on compelling interim data with rapid incorporation into KDIGO treatment guidelines


Marketing exclusivity period without generic competition or challenge – 7 years in US, 10 years in EU, with opportunity to extend on paediatric indication – in addition to comprehensive patent/IP strategy

Regulatory assistance and guidance from regulators in the design of an overall drug development plan



1. Cost of Sparsentan - approved for IgAN https://endpts.com/fda-clears-traveres-rare-kidney-disease-drug-will-come-with-rems-program; Cost of Tarpeyo Wholesale acquisition cost (WAC) of \$14,160 for a 30-day supply\$170k /year https://www.calliditas.se/en/wp-content/uploads/sites/2/2018/01/fda-approvalwebcast-presentation.pdf; 2. 2018, IQVIA, Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments

Orphan disease treatment – case study



imerix

FSGS has large unmet medical need

With no therapies approved for the treatment of FSGS:

- patients are treated with other medications off-label, including angiotensin receptor blockers
- patients likely end up on dialysis and/or kidney transplant
- current market specifically for FSGS does not exist

21% forecast global market growth year on year¹

220,000 diagnosed patients (7MM)¹

US\$9,900 cost per month² Example only** Final market price TBD

Estimated US\$3.27 billion by 2032 (7MM)¹





Increased prevalence of



Potential increase in therapeutic options





Increase in diagnostic tests



1. Focal segmental glomerulosclerosis – Market Insight (2022), Epidemiology and market forecast – 2032 Delve Insight; 2. Cost of Sparsentan - approved for IgAN https://endpts.com/fda-clears-traveres-rarekidnev-disease-drug-will-come-with-rems-program; Cost of Tarpeyo Wholesale acquisition cost (WAC) of \$14,160 for a 30-day supply\$170k /year https://www.calliditas.se/en/wp-content/uploads/sites/2/2018/01/fda-7 approval-webcast-presentation.pdf; 3. Personal communication (2022) FSGS sales forecasts in China; 4. https://www.researchandmarkets.com/reports/5309873/focal-segmental-glomerulosclerosis-global;

DMX-200 – working on inflammatory signalling pathway

A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR)



imerix

ACTION3 Clinical trial status

FSGS CLINICAL STUDY

Initiate clinical

sites

Part 1

Å randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB

Screening (2-4 wks) and stabilisation (4-6 wks) of

background medication

Part 1: dose

n=72 patients

ARB + placebo

ARB + DMX-200

35 weeks + analysis time

Part 1: interim

data outcome

~H2 2023*

Data outcome

anticipated end 2023*

- Part 1: global study recruiting across ~70 sites in 11 countries:
 - Geographically diverse to meet differing regulatory requirements;
- Part 2: additional countries and sites will open following Part 1 outcome
 - Increases recruitment potential

35 weeks +

analysis time

Part 2:

Recruit/dose

n=144 patients


• Increases commercial opportunity in each territory

Part 2 interim

data outcome

Potential to submit for accelerated marketing

approval**



Recruit 72

patients

Part 1

Continue to final trial

endpoint;

n=286: 104 weeks

9

Late stage, phase 3 clinical development asset





Near term Phase 3 interim analysis, and potential accelerated approval pathway

Advanced partnering negotiations with offers received from multiple parties for various territories¹

Comprehensive development plan to ensure commercial ready

Orphan Drug status providing protection through data exclusivity²

Growing global market forecasted to exceed \$3b by 2032³



Strong progress to date in recruitment, managed by an experienced team and global CRO

Dimerix

A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.



Well positioned to deliver against strategic plan

ASX:DXB

Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. investor@dimerix.com

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.